NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
Conditions
- Breast Cancer
- Triple-negative Breast Cancer
Interventions
- DRUG: Sacituzumab govitecan
- DRUG: Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]
- DRUG: SoC Chemotherapy
Sponsor
West German Study Group
Collaborators